CDK4 and breast carcinoma: In breast cancer patients receiving a combination of RT and CDK4/6 inhibitors as curative adjuvant treatment, pulmonary toxicity is a concern and requires careful monitoring, particularly in Asian populations, even using modern RT techniques to limit the lung exposure dose.